Amgen Sues Samsung Bioepis Over Blockbuster Bone Drug Biosimilar

August 16, 2024 |

Amgen filed a lawsuit against Samsung Bioepis for infringing 34 patents that cover denosumab, the active ingredient in Prolia and Xgeva, drugs used to treat bone loss.
Source: Drug Industry Daily